CEACAM5 and neoplasm: Moreover, tissue biopsies cannot fully monitor the dynamic changes in tumor burden, and circulating biomarkers currently used, including carcinoembryonic antigen (CEA) and cancer antigen 15‐3 (CA15‐3), have low sensitivity in some patient populations (Wu et al., 2014).